Show Notes
This episode examines the need for and promise of xenotransplantation, considering first the plight of patients and then the progress being made by researchers. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2309946.
More from Intention to Treat
The ripple effects of U.S. anti-DEI policies extend far beyond individual labs: scientific discovery is slowing, early‑career investigators are reconsidering their futures, and the pipeline of medical school applicants is shifting in real time. A full transcript of this episode is available at https://www.nejm.org/doi/full/10.1056/NEJMp2601982.
The use of race in medicine is harming patients. What is being done to move away from these practices and to change a culture of medicine based on the false premise that race is biological? A full transcript of this episode is available at https://www.nejm.org/doi/full/10.1056/NEJMp2601981.
We now know that humans are more than 99.9% genetically alike. So why does medicine still link certain diseases to race? And what do genetics actually tell us about race, ancestry, and disease? A full transcript of this episode is available at https://www.nejm.org/doi/full/10.1056/NEJMp2601980.
How did a drug for congestive heart failure get approved and marketed for Black people only?
The story of the pulse oximeter demonstrates that sometimes consideration of race is critical to diagnosis and treatment — as came starkly into light during the Covid-19 pandemic. A full transcript of this episode is available at https://www.nejm.org/doi/full/10.1056/NEJMp2601977.